Aktienanalyse zu Tvardi Therapeutics Inc (TVRD)TVRDTvardi Therapeutics Inc

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3. It operates in the Healthcare sector.

Tvardi Therapeutics is a good buy right now, trading at $0.9655 with a recent RSI of 65.93 suggesting strong momentum. Analysts have set a price target of $14, which represents a potential upside of over 1,400% from the current price. The recent 5-day price change of +21.78% indicates positive short-term momentum, while the projected trajectory suggests a potential increase of 151.76% based on historical patterns. However, the company faces risks with a high net income loss of $6.8 million in Q1 2026, which could impact investor confidence.